Healthcare and Life Science
Medicilon neural system disease models help our clients advance novel drug development
Medicilon Pharmacodynamics Department can deliver multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsant, anti-Parkinson's drugs, and anti-schizophrenia drugs. Those models can effectively e...
impulse 2025 - the entrepreneurship programme for innovators is now open for applications
impulse is an action-learning programme designed to catalyse the development of high-potential innovation into commercial propositions, guided by experienced entrepreneurs and mentors from the Cambridge innovation cluster. The 3-month hybrid programme – which runs from 29...
Tristan backs £300m+ life sciences platform
Tristan Capital Partners’ debt fund has refinanced a £310m prime life science portfolio located across Cambridge and Oxford, Green Street News can reveal. ...
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic indications, including oncologyLond...
Metrion Biosciences appoints Lee Patterson as CEO
Significant CRO C-suite experience expected to drive growth and commercial expansion into global marketsCambridge, UK, 25 November 2024: Metrion Biosciences, the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, announces the appoint...
Guardtech Group hoping to end golden year with more success at SME National Business Awards
Suffolk contamination control experts looking to add Best Enterprising Business prize to epic 2024 awards haul at glitzy Wembley Stadium showpiece on 6 December ...
Analytics for clinical development strategy: Integrated optimization of an oncology program
Achieving a return on invested capital (ROIC) that exceeds the cost of capital remains a challenge for pharmaceutical R&D. To make progress, there needs to be consistent and rigorous modeling of the clinical and commercial determinants of ROIC. In the second of three articles, CRA’...
CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?
Aduhelm was the first FDA-approved disease-modifying treatment for Alzheimer’s, sparking debate among providers, regulators, and patients. Aduhelm received a controversial accelerated approval from the FDA in June 2021, a decision that balanced the lack of consensuses among the scientif...
Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D
Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This...
Infertility - A public health concern
The World Health Organization (WHO) estimates that one out of six people globally are impacted by the inability to conceive a child. Over the last decade, countries around the world have seen a decline in total fertility rates, most notably in economically developed countries withi...